• S Schreiber, S Nikolaus, and P Rosenstiel.
• Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität zu Kiel, Schittenhelmstr. 12, 24105, Kiel, Deutschland, s.schreiber@mucosa.de.
• Internist (Berl). 2014 Aug 1; 55 (8): 889-97.

AbstractThe complex microbiome of the human gut contains an excessive amount of genetic information that is more than 100-fold larger than the human genome. In patients with inflammatory bowel disease diversity of the gut microbiome is significantly reduced and moreover specific phyla are overrepresented or underrepresented. However, the functional capacity of the microflora to generate certain metabolic products containing lipids or amino acids- and more complex regulatory substances is more important that the mere annotation of the microorganisms. Modern pharmacological approaches target the functional capacity and constitution of the microbiome. An important strategy is the development of controlled release formulations that deliver defined lipid, carbohydrate or amino acid products derived from nutritional components targeting gut areas distal to the absorption zones of the upper gastrointestinal tract.

15 keywords...

hide…